Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction

Producción Científica

Detalles Bibliográficos
Autores: Lima-Posada, Ixchel, Stephan, Yohan, Soulié, Matthieu, Bonnard, Benjamin, Nicol, Lionel, Kolkhof, Peter, Jaisser, Frederic, Mulder, Paul, Palacios Ramírez, Roberto
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universidad de Valladolid
Repositorio:UVaDOC. Repositorio Documental de la Universidad de Valladolid
OAI Identifier:oai:uvadoc.uva.es:10324/65924
Acceso en línea:https://doi.org/10.3390/ijms24032536
https://uvadoc.uva.es/handle/10324/65924
Access Level:acceso abierto
Palabra clave:diabetes
heart failure
mineralocorticoid receptor antagonist
diastolic dysfunction
finerenone
id ES_d07945abc4c0b1bf0d062a5e40ba6089
oai_identifier_str oai:uvadoc.uva.es:10324/65924
network_acronym_str ES
network_name_str España
repository_id_str
spelling Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection FractionLima-Posada, IxchelStephan, YohanSoulié, MatthieuBonnard, BenjaminNicol, LionelKolkhof, PeterJaisser, FredericMulder, PaulPalacios Ramírez, Robertodiabetesheart failuremineralocorticoid receptor antagonistdiastolic dysfunctionfinerenoneProducción CientíficaThe mineralocorticoid receptor (MR) plays an important role in the development of chronic kidney disease (CKD) and associated cardiovascular complications. Antagonizing the overactivation of the MR with MR antagonists (MRA) is a therapeutic option, but their use in patients with CKD is limited due to the associated risk of hyperkalemia. Finerenone is a non-steroidal MRA associated with an improved benefit-risk profile in comparison to steroidal MRAs. In this study, we decided to test whether finerenone improves renal and cardiac function in male hypertensive and diabetic ZSF1 rats as an established preclinical HFpEF model. Finerenone was administered at 10 mg/kg/day for 12 weeks. Cardiac function/hemodynamics were assessed in vivo. ZSF1 rats showed classical signs of CKD with increased BUN, UACR, hypertrophy, and fibrosis of the kidney together with characteristic signs of HFpEF including cardiac fibrosis, diastolic dysfunction, and decreased cardiac perfusion. Finerenone treatment did not impact kidney function but reduced renal hypertrophy and cardiac fibrosis. Interestingly, finerenone ameliorated diastolic dysfunction and cardiac perfusion in ZSF1 rats. In summary, we show for the first time that non-steroidal MR antagonism by finerenone attenuates cardiac diastolic dysfunction and improves cardiac perfusion in a preclinical HFpEF model. These cardiac benefits were found to be largely independent of renal benefits.2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://doi.org/10.3390/ijms24032536https://uvadoc.uva.es/handle/10324/65924reponame:UVaDOC. Repositorio Documental de la Universidad de Valladolidinstname:Universidad de ValladolidIngléshttps://www.mdpi.com/1422-0067/24/3/2536info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/4.0/oai:uvadoc.uva.es:10324/659242026-06-13T12:44:47Z
dc.title.none.fl_str_mv Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
title Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
spellingShingle Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
Lima-Posada, Ixchel
diabetes
heart failure
mineralocorticoid receptor antagonist
diastolic dysfunction
finerenone
title_short Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
title_full Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
title_fullStr Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
title_full_unstemmed Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
title_sort Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
dc.creator.none.fl_str_mv Lima-Posada, Ixchel
Stephan, Yohan
Soulié, Matthieu
Bonnard, Benjamin
Nicol, Lionel
Kolkhof, Peter
Jaisser, Frederic
Mulder, Paul
Palacios Ramírez, Roberto
author Lima-Posada, Ixchel
author_facet Lima-Posada, Ixchel
Stephan, Yohan
Soulié, Matthieu
Bonnard, Benjamin
Nicol, Lionel
Kolkhof, Peter
Jaisser, Frederic
Mulder, Paul
Palacios Ramírez, Roberto
author_role author
author2 Stephan, Yohan
Soulié, Matthieu
Bonnard, Benjamin
Nicol, Lionel
Kolkhof, Peter
Jaisser, Frederic
Mulder, Paul
Palacios Ramírez, Roberto
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv diabetes
heart failure
mineralocorticoid receptor antagonist
diastolic dysfunction
finerenone
topic diabetes
heart failure
mineralocorticoid receptor antagonist
diastolic dysfunction
finerenone
description Producción Científica
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.3390/ijms24032536
https://uvadoc.uva.es/handle/10324/65924
url https://doi.org/10.3390/ijms24032536
https://uvadoc.uva.es/handle/10324/65924
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://www.mdpi.com/1422-0067/24/3/2536
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:UVaDOC. Repositorio Documental de la Universidad de Valladolid
instname:Universidad de Valladolid
instname_str Universidad de Valladolid
reponame_str UVaDOC. Repositorio Documental de la Universidad de Valladolid
collection UVaDOC. Repositorio Documental de la Universidad de Valladolid
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420177025662976
score 15.300724

Similares en LA Referencia